

Tremfya SC (guselkumab)
Effective 08/16/2026

Plan	☐ MassHealth UPPL ☒ Commercial/Exchange	Program Type	☒ Prior Authorization ☐ Quantity Limit ☐ Step Therapy
Benefit	☒ Pharmacy Benefit ☐ Medical Benefit		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Medical Benefit Pharmacy Benefit	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions			

Overview

Tremfya (guselkumab) is an interleukin-23 (IL-23) antagonist indicated for the treatment of:

- Moderate-to-severe plaque psoriasis
- Active psoriatic arthritis
- Moderately to severely active ulcerative colitis
- Moderately to severity active Crohn's disease

Coverage Guidelines

If member is new to the plan (as evidenced by coverage effective date of less than or equal to 90 days), submission of medical records documenting that the member is currently receiving treatment with the requested drug, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Authorization may be granted if the member meets all of the following diagnosis-specific criteria:

Moderate to severe plaque psoriasis

1. Diagnosis of moderate to severe plaque psoriasis
2. At least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) are affected.
3. ONE of the following:
 - a. Minimum duration of 4-week trial and failure, contraindication, or intolerance to ONE of the following topical therapies
 - i. Corticosteroids (e.g., betamethasone, clobetasol)
 - ii. Vitamin D analogs (e.g., calcitriol, calcipotriene)
 - iii. Tazarotene
 - iv. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
 - v. Anthralin
 - vi. Coal tar
 - b. Member has severe psoriasis that warrants a biologic DMARD or targeted synthetic therapy as first-line therapy

Active psoriatic arthritis (PsA)

1. Diagnosis of active psoriatic arthritis (PsA)
2. ONE of the following:
 - a. Actively inflamed joints
 - b. Dactylitis
 - c. Enthesitis
 - d. Axial disease
 - e. Active skin and/or nail involvement

Moderately to severely active ulcerative colitis (UC)

1. Diagnosis of moderately to severely active ulcerative colitis
2. ONE of the following:
 - a. Subcutaneous formulation will be used as maintenance therapy following IV induction
 - b. ALL of the following
 - i. ONE of the following:
 1. Trial and failure, contraindication, or intolerance to ONE of the following conventional therapies:
 - a. 6-mercaptopurine
 - b. Aminosalicylate (e.g., mesalamine, olsalazine, sulfasalazine)
 - c. Azathioprine
 - d. Corticosteroids (e.g., prednisone)
 2. Disease severity warrants systemic biologic or targeted synthetic therapy as first-line therapy
 - ii. Member will use subcutaneous injection for induction dosing

Moderately to severely active Crohn's disease

1. Diagnosis of moderately to severely active Crohn's disease
2. ONE of the following:
 - a. Subcutaneous formulation will be used as maintenance therapy following IV induction
 - b. ALL of the following:
 - i. ONE of the following:
 1. Member has had trial and failure, intolerance, or contraindication to ONE of the following conventional therapies:
 - a. 6-mercaptopurine
 - b. Azathioprine
 - c. Corticosteroids (e.g., prednisone)
 - d. Methotrexate
 2. Disease severity warrants systemic biologic or targeted synthetic therapy as first-line therapy
 - ii. Member will use subcutaneous injection for induction dosing

Continuation of Therapy

Requests for reauthorization for all diagnoses will be approved when all of the following criteria are met:

1. Submission of medical records (e.g., chart notes) documenting an improvement in the member's condition, as evidenced by low disease activity or improvement in signs and symptoms of the condition

Limitations

1. Initial approvals and reauthorizations will be granted for 24 months.



- The following quantity limits apply:

Drug Name and Dosage Form	Quantity Limitations
Crohn's Disease and Ulcerative Colitis induction pack, SC: Tremfya 200 mg/2 mL	400 mg (4 mL) at weeks 0, 4, and 8 (3 packs per 365 days)
Tremfya 100mg/mL prefilled syringe, autoinjector (plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease)	100 mg (1 mL) every 8 weeks
Tremfya 200 mg/2 mL prefilled syringe, autoinjector (ulcerative colitis, Crohn's disease)	200 mg (2 mL) every 4 weeks

References

- Elmets CA, Korman NJ, Farley Prater E, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. *J Am Acad Dermatol* 2021;84:432-70.
- Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4: Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. *J Am Acad Dermatol*. 2009; 61:451-485.
- Reich K, Armstrong, AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. *Am J Clin Dermatol*. 2017;76(3):418-431.
- Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. *Arthritis Rheumatol*. 2019;71(1):5-32.
- Tremfya (guselkumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; September 2025.

Review History

02/26/18 – Reviewed

06/01/18 – Implemented

02/20/19 – Updated

11/20/19 – Added Skyrizi as a preferred trial for PS

07/19/2021- Reviewed at July P&T; started and stabilized statement updated to include “new to AllWays Health Partners”; Added criteria for PsA indication; overview updated; references updated; loading dose added to limitations. Effective 10/01/2021.

09/21/2022 – Reviewed and Updated for Sept P&T; added Skyrizi as a preferred agent for diagnosis of psoriatic arthritis. Effective 11/1/22.

11/15/2023 – Reviewed and Updated for Nov P&T; For Plaque Psoriasis: updated BSA requirement to > 3% BSA or crucial body area. Removed TB requirement. Updated requirement of topical therapies. For psoriatic arthritis: updated approval criteria; Updated continuation of therapy criteria to include examples of improvement in symptoms. Effective 1/1/24

10/9/2024- Reviewed and updated for October P&T. Added criteria for ulcerative colitis to the policy. Updated Limitations section to specify that Tremfya IV will only be approved for the treatment of ulcerative colitis. Added quantity limits for Tremfya IV and Tremfya 200 mg/2mL prefilled syringe/autoinjector. For plaque psoriasis removed age requirement and removed requirement for documentation for 4-week trial with a conventional therapy. Updated continuation of therapy criteria to require documentation supporting improvement in the member's condition as evidenced by low disease activity or improvement in signs and symptoms of the condition. Effective 1/1/2025.



05/14/2025 – Reviewed and updated for May P&T. Updated criteria for ulcerative colitis to remove disease characteristic requirement and allow for approval if disease severity warrants systemic biologic as first-line therapy. Added criteria for Crohn’s disease. Updated listed quantity limitations. Effective 07/01/2025.

07/09/2025 – Reviewed and updated for July P&T. Updated approval length for Tremfya IV to 12 weeks. Effective 09/01/2025.

10/08/2025 – Reviewed and updated for October P&T. Effective 11/15/2025: Updated policy to indicate that the SC induction pack will be approved for loading doses of ulcerative colitis, as well. Updated policy to reflect that only one route of administration (IV or SC) will be approved for loading doses of ulcerative colitis. Effective 1/1/2026: Updated policy to indicate that it no longer applies to the medical benefit. Adding language for the SC formulation to the UC and CD diagnoses to require that either the member has either received IV induction therapy or will use the SC formulation after IV induction or will use the SC formulation as a loading dose. Effective 01/01/2026.

11/12/2025 – Reviewed and updated for November P&T. updated title of policy “Tremfya SC.” Effective 01/01/2026.

03/11/2026 – Reviewed and updated for March P&T. Administrative update - changing verbiage in reauthorization criteria from “documentation is submitted” to “submission of medical records (e.g., chart notes...” and updating language for members who are new to the Plan. In limitations section clarified indications for various strengths. Effective 05/01/2026.

04/15/2026 – Reviewed and updated at April P&T. Updated previous trial language for plaque psoriasis, ulcerative colitis and Crohn’s disease, allowing for bypassing conventional therapy if member has severe disease that warrants a biologic DMARD or targeted synthetic therapy as first-line therapy. For UC and CD, updated criteria, allowing for approval of the SC formulation if the member will be inducted with the IV. Effective 08/16/2026.

